Biomarker-Driven Lung Cancer

Resection of stage I lung adenocarcinoma can lead to 5-year survival rates of up to 87%, but whether adjuvant therapy can improve overall survival (OS) in this subset of patients is not yet clear.

James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.

A new drug application for brigatinib for patients with metastatic ALK-positive NSCLC who are resistant to prior crizotinib (Xalkori) has been granted priority review by the FDA.

A recent phase III trial showed custirsen combined with docetaxel failed to significantly extend overall survival (OS) compared with docetaxel alone as a second-line treatment for patients with NSCLC.

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the future role of PD-L1 testing in lung cancer.

Pembrolizumab (Keytruda) has received FDA approval for the frontline treatment of patients with metastatic non­–small cell lung cancer (NSCLC) whose tumors have ≥50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

Heather Wakelee, MD, associate professor of medicine at Stanford University Medical Center, discusses a recent trial looking at atezolizumab for NSCLC treatment.

Puneeth Iyengar, MD, PhD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the two potential roles immunotherapy could play in the treatment of NSCLC.

Atezolizumab has received FDA approval for the treatment of patients with metastatic NSCLC who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring <em>EGFR</em> or <em>ALK</em> abnormalities.&nbsp;

Although there are no drugs yet that target TP53 mutations in any tumor type, a recent analysis of a non&ndash;small cell lung cancer (NSCLC) sample set raises the prospect that a more detailed understanding of this aberration could eventually help direct therapy.

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the role of lenvatinib in treating patients with non-small cell lung cancer (NSCLC).

Benjamin P. Levy, MD, discusses how Myriad&#39;s myPlan addresses the risk of recurrence in lung cancer.

Results of a recent randomized trial showed first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1&ndash;positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Almost 40% of patients with resected early-stage non&ndash;small cell lung cancer (NSCLC) had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non&ndash;small cell lung cancer (NSCLC) who progressed after first-line crizotinib.